Dermatology Billing — Built for Your Practice
A single dermatology visit can generate four billable line items in fifteen minutes — E&M, biopsy, destruction, and a complex closure — and every one of them lives or dies on a measurement, a count, or a modifier that either got documented or didn't. Most billing systems aren't built for that level of per-encounter detail. Ours is.
The real risk in dermatology billing isn't knowing which code exists — it's whether the lesion size with margins was recorded, whether the destruction count matches what was actually treated, and whether the payer classifies the procedure as medically necessary or cosmetic. We catch those documentation gaps before the claim goes out, not after it comes back denied.
What's Costing Dermatology Practices Money Right Now
These are the specific, avoidable spots where dermatology revenue quietly disappears before a claim ever gets appealed.
Excision codes get billed by lesion size alone when the code actually depends on lesion diameter plus surgical margin — a routine one-level underbill on every excision where margin isn't documented.
Destruction quantity gets miscounted — 17110 billed when 17111 applies, or actinic keratoses billed as one flat code instead of 17000 plus 17003 for every additional lesion.
A Mohs stage gets billed without the frozen section documentation to support it, and payers deny that stage outright on audit.
Cosmetic and medically necessary procedures get billed the same way when payer coverage rules actually treat them completely differently, depending on the diagnosis.
Biologic drug prior authorizations (Dupixent, Skyrizi, Tremfya) lapse mid-treatment, and the administration claim denies — sometimes retroactively across multiple visits.
Dermatopathology gets billed under the wrong NPI when a specimen was actually read by an outside lab, not the practice.
Top Dermatology Claim Denial Reasons — and How We Eliminate Them
Most Dermatology denials are preventable. Our team knows exactly what to look for before submission.
❌ Excision Code — Wrong Size Band Selected
Excision codes are grouped in narrow diameter bands. 11401 is 0.6–1.0 cm; 11402 is 1.1–2.0 cm. When the operative note records the lesion size but not the surgical margin, coders often bill based on lesion size alone — underbilling by one or two code levels.
✓ Our Fix
We require that the lesion diameter plus surgical margins (in cm) appear in the procedure note. We calculate the total diameter, select the correct code, and flag incomplete documentation before submission rather than guessing down to avoid audit risk.
❌ Destruction Quantity Count Error
Billing 17110 when 17111 applies (or vice versa) is a common charge capture error. Missing the transition from first actinic keratosis (17000) to additional lesions (17003) means patients with 8 AKs treated generate one unit of billing instead of seven.
✓ Our Fix
We require lesion count documentation for every destruction note. Our charge entry workflow includes a mandatory lesion count field that triggers the correct code and unit combination automatically.
❌ Mohs Stage Documentation Incomplete
Each Mohs stage requires a separate, physician-signed record that documents the tissue orientation, size, and frozen section results. Payers audit Mohs claims specifically for per-stage documentation. A missing map or lab report results in denial of that stage.
✓ Our Fix
We don't bill a Mohs stage until we have received and reviewed the corresponding frozen section documentation. Our Mohs billing checklist cross-references stages billed against documentation on file for every case.
❌ Biologic Drug Prior Authorization Lapse
Biologics like Dupixent, Skyrizi, and Tremfya require prior authorization that expires and must be renewed. A lapse results in the drug administration claim being denied — sometimes retroactively for multiple dates of service.
✓ Our Fix
We track biologic authorization expiration dates 45 days in advance and initiate renewal paperwork before coverage lapses. If a payer denies renewal, we file a medical necessity appeal with clinical documentation and peer-reviewed literature supporting the treatment.
Our Dermatology Billing Process, Start to Finish
Measurement-Driven Charge Capture
Excision and destruction codes are assigned from the documented lesion diameter, surgical margin, and lesion count in the procedure note — never estimated or defaulted.
Eligibility & Prior Authorization
We track biologic drug authorizations (Dupixent, Skyrizi, Tremfya, and others) 45 days before expiration and submit renewals before a scheduled administration date arrives without active authorization.
Mohs & Documentation Compliance Audits
Every Mohs stage is checked against its frozen section and physician-signed record before billing — a stage is never submitted until the supporting documentation is on file.
Denial Prevention & Recovery
Cosmetic vs. medically necessary determinations are verified against a payer-specific database before submission, and any denial is tracked, corrected, and appealed with supporting literature when needed.
Reporting & Revenue Insights
A real-time dashboard shows collection rate, Mohs stage accuracy, and denial trends by procedure type, so you always know where your dermatology revenue stands.
Everything Included with ZenoMedix RCM Dermatology Billing
- Mohs surgery stage billing with frozen section documentation verification
- Excision code sizing based on documented lesion diameter + margins
- Destruction quantity billing — per-lesion accuracy
- Cosmetic vs. medical coverage determination by payer
- Biologic drug prior authorization and administration billing
- Dermatopathology billing under the correct provider NPI
- 95%+ collection rate for dermatology practices
- Phototherapy prior authorization management
Complete Revenue Cycle for Dermatology Practices
What Sets ZenoMedix RCM Apart in Dermatology Billing
Not every billing company is built the same way. Here's what changes when your dermatology claims run through ours.
Derm-Trained Coders, Not Generalists
Our coders read the operative note for exact measurements and counts — lesion diameter plus margin, destruction quantity, Mohs stage documentation — before assigning a code, not a template.
Every Denial Appealed, Never Written Off
Biologic authorization denials and Mohs stage disputes are tracked, corrected at the root cause, and appealed with clinical documentation and literature when needed.
Pay Only When We Collect
Percentage-based pricing tied to what we actually collect for your practice, with no long-term contract.
Real-Time Visibility Into Your Revenue
A live dashboard shows collection rate, denial trends, and Mohs/excision billing accuracy — no waiting on a monthly PDF.
We Partner With Every Type of Dermatology Practice
Mohs Micrographic Surgery Practices
Per-stage billing (17311–17315) verified against frozen section documentation before each stage is submitted.
General Surgical Dermatology
Excision (11400–11646) and destruction (17000/17003, 17110/17111) coded from documented size, margin, and lesion count.
Medical Dermatology & Biologics Practices
Prior authorization tracking for biologic injectables (Dupixent, Skyrizi, Tremfya) with renewal filed 45 days before expiration.
Cosmetic-Adjacent Practices
Payer-specific cosmetic vs. medically necessary determinations, with claims correctly split and a separate self-pay invoice generated for the cosmetic component.
Phototherapy & Light-Based Treatment Practices
Actinotherapy (96900) billing with prior authorization management for ongoing phototherapy courses.
In-House Dermatopathology Practices
Professional component billing (-26) under the reading physician's NPI when specimens are read in-house, correctly separated from outside-lab referrals.
Dermatology Billing Available in All 50 States
From California to New York, our Dermatology billing specialists understand your state's Medicaid program, payer mix, and compliance requirements.
Find Your State →Dermatology Billing FAQ
Excision codes (11400–11646) are selected by three variables: body location (trunk/extremities vs. face/ears/eyelids/nose/lips vs. scalp/neck/hands/feet/genitalia), lesion type (benign vs. malignant), and excised diameter. The excised diameter is the lesion diameter plus surgical margins — not just the lesion size. We require both measurements in the operative note before assigning a code. If only the lesion size is documented, we flag the note for addendum before billing.
We maintain a payer-specific database of cosmetic vs. medically necessary determinations for hundreds of common dermatology procedures. For borderline cases — excess skin removal after weight loss, hair loss treatment under specific conditions, rosacea with documented impairment — we bill with supporting medical necessity documentation. When a procedure has both a covered and a cosmetic component (e.g., blepharoplasty where part is functional and part is cosmetic), we correctly split the claim and generate a separate self-pay invoice for the cosmetic portion.
When your dermatologist reads specimens in-house, the pathology professional component (88302–88309) is billed under the reading physician's NPI with modifier -26. The technical component (processing and staining) may be billed separately under the lab's NPI if applicable. When specimens are sent to an outside lab, we bill only the biopsy procedure code under the treating dermatologist — no pathology component. Billing pathology when it was performed by an outside lab is a common compliance mistake we prevent.
For 12 actinic keratoses treated on the same date, you bill: 17000 (first lesion) × 1 unit, plus 17003 (each additional, 2–14) × 11 units. The total is 12 units across two codes. This is frequently miscoded as 17110 (general benign destruction) which pays at a different rate and requires different documentation. The same logic applies to benign lesion destruction under 17110/17111: 17110 covers up to 14 lesions destroyed in a single session, while 17111 applies once the count reaches 15 or more lesions in that same session — a different threshold structure from the per-lesion AK codes, and one that's easy to apply incorrectly if the two code families are confused. We code destruction claims precisely to ensure accurate reimbursement for the volume of lesions treated.
Each Mohs stage (17311 for the first stage, 17312 for each additional stage) has to be supported by its own physician-signed record documenting the tissue orientation, the specimen size, and the frozen section results for that specific stage — not a single summary note covering the whole case. Payers audit Mohs claims specifically for per-stage documentation, and a missing tissue map or lab report results in denial of that individual stage, even when the other stages of the same case are properly supported. We don't bill a Mohs stage until we've received and reviewed its corresponding frozen section documentation, and our billing checklist cross-references every stage billed against documentation on file for that case.
Biologic medications administered in the office follow a specific billing workflow: HCPCS drug code (J-code or Q-code) + administration code (96401 or similar) + the prior authorization documentation. We manage the full cycle: obtaining initial authorization with appropriate diagnosis codes, submitting the claim with the exact drug dosage billed in the correct unit of measure per the J-code descriptor, and tracking auth renewals 45 days in advance. Patient assistance program coordination is available for patients with cost-sharing challenges.
Dermatology Billing Results — By the Numbers
See How Much More Your Dermatology Practice Can Collect
- ✓Specialty-specific coding analysis
- ✓Denial pattern review
- ✓Payer mix assessment
- ✓Revenue recovery estimate